1 |
Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction[J]. J Am Coll Cardiol, 2012, 60(16): 1581-1598.
|
2 |
Ladue JS, Wroblewski F, Karmen A. Serum glutamic oxaloacetic transaminase activity in human acute transmural myocardial infarction[J]. Science, 1954, 120(3117): 497-499.
|
3 |
Apple FS, Jesse RL, Newby LK, et al. National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: Analytical issues for biochemical markers of acute coronary syndromes[J]. Circulation, 2007, 115(13): 352-355.
|
4 |
Mair J, Artner-Dworzak E, Lechleitner P, et al. Early diagnosis of acute myocardial infarction by a newly developed rapid immunoturbidimetric assay for myoglobin[J]. Br Heart J, 1992, 68(5): 462-468.
|
5 |
Melanson SF, Lewandrowski EL, Januzzi JL, et al. Reevaluation of myoglobin for acute chest pain evaluation: Would false-positive results on "first-draw" specimens lead to increased hospital admissions?[J]. Am J Clin Pathol, 2004, 121(6): 804-808.
|
6 |
McCord J, Nowak RM, Hudson MP, et al. The prognostic significance of serial myoglobin, troponin I, and creatine kinase-MB measurements in patients evaluated in the emergency department for acute coronary syndrome[J]. Ann Emerg Med, 2003, 42(3): 343-350.
|
7 |
Lin JC, Apple FS, Murakami MM, et al. Rates of positive cardiac troponin I and creatine kinase MD mass among patients hospitalized for suspected acute coronary syndromes[J]. Clin Chem, 2004, 50(2): 333-338.
|
8 |
Saenger AK. A tale of two biomarkers: The use of troponin and CK-MB in contemporary practice[J]. Clin Lab Sci, 2010, 23(3): 134-140.
|
9 |
Hedstrom E, Astrom-Olsson K, Ohlin H, et al. Peak CKMB and cTnT accurately estimates myocardial infarct size after reperfusion[J]. ancer Cell Int, 2007, 41(1): 44-50.
|
10 |
Schulz O, Kromer A. Cardiac troponin I: a potential marker of exercise intolerance in patients with moderate heart failure[J]. Am Heart J, 2002, 144(2): 351-358.
|
11 |
Katus HA, Remppis A, Neumann FJ, et al. Diagnostic efficiency of troponin T measurements in acute myocardial infarction[J]. Circulation, 1991, 83(3): 902-912.
|
12 |
Tiwari RP, Jain A, Khan Z, et al. Cardiac troponins I and T: molecular markers for early diagnosis, prognosis, and accurate triaging of patients with acute myocardial infarction[J]. Mol Diagn Ther, 2012, 16(6): 371-381.
|
13 |
Morrow DA, Cannon CP, Jesse RL, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical characteristics and utilization of biochemical markers in acute coronary syndromes[J]. Circulation, 2007, 115(13): 356-375.
|
14 |
Hirsch A, Windhausen F, Tijssen JG, et al. Long-term outcome after an early invasive versus selective invasive treatment strategy in patients with non-ST-elevation acute coronary syndrome and elevated cardiac troponin T (the ICTUS trial): A follow-up study[J]. Lancet, 2007, 369(9564): 827-835.
|
15 |
deFilippi CR, Tocchi M, Parmar RJ, et al. Cardiac troponin T in chest pain unit patients without ischemic electrocardiographic changes: Angiographic correlates and long-term clinical outcomes[J]. J Am Coll Cardiol, 2000, 35(7): 1827-1834.
|
16 |
Hamm CW, Bassand JP, Agewall S, et al. [ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. The task force for the management of acute coronary syndromes (ACS in patients presenting without persistent st-segment elevation of the european society of cardiology (ESC)][J]. G Ital Cardiol, 2012, 13(3): 171-228.
|
17 |
Verheugt FW.[Acute coronary syndrome: Technological improvements in diagnostics and therapy][J]. Ned Tijdschr Geneeskd, 1999, 143(45): 2241-2246.
|
18 |
Keller T, Zeller T, Ojeda F, et al. Serial changes in highly sensitive troponin i assay and early diagnosis of myocardial infarction[J]. JAMA, 2011, 306(24): 2684-2693.
|
19 |
Babuin L, Jaffe AS. Troponin: The biomarker of choice for the detection of cardiac injury[J]. CMAJ, 2005, 173(10): 1191-1202.
|
20 |
Newby LK, Jesse RL, Babb JD, et al. ACCF 2012 expert consensus document on practical clinical considerations in the interpretation of troponin elevations: A report of the American College of Cardiology Foundation task force on clinical expert consensus documents[J]. J Am Coll Cardiol, 2012, 60(23): 2427-2463.
|
21 |
Panteghini M. Acute coronary syndrome: Biochemical strategies in the troponin era[J]. Clin Chim Acta, 2002, 122(4)1428-1435.
|
22 |
Randhawa MS, Dhillon AS, Taylor HC, et al. Diagnostic utility of cardiac biomarkers in discriminating Takotsubo cardiomyopathy from acute myocardial infarction[J]. J Card Fail, 2014, 20(1): 2-8.
|
23 |
Liu WX, Zhao H. [Relationship between plasma n-terminal pro-brain natriuretic peptide and grace risk stratification in non-st-segment elevation acute coronary syndrome][J]. Zhonghua Xin Xue Guan Bing Za Zhi, 2012, 40(5): 373-377.
|
24 |
Cowie MR, Jourdain P, Maisel A, et al. Clinical applications of b-type natriuretic peptide (bnp) testing[J]. Eur Heart J, 2003, 24(19): 1710-1718.
|
25 |
Jernberg T, James S, Lindahl B, et al. Nt-proBNP in unstable coronary artery disease--experiences from the FAST, GUSTO IV and FRISC II trials[J]. Eur J Heart Fail, 2004, 6(3): 319-325.
|
26 |
Tillett WS, Francis T. Serological reactions in pneumonia with a non-protein somatic fraction of pneumococcus[J]. J Exp Med, 1930, 52(4)561-571.
|
27 |
de Ferranti S, Rifai N. C-reactive protein and cardiovascular disease: A review of risk prediction and interventions[J]. Clin Chim Acta, 2002, 317(1-2): 1-15.
|
28 |
Pietila K, Hermens WT, Harmoinen A, et al. Comparison of peak serum C-reactive protein and hydroxybutyrate dehydrogenase levels in patients with acute myocardial infarction treated with alteplase and streptokinase[J]. Am J Cardiol, 1997, 80(8): 1075-1077.
|
29 |
Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention[J]. Circulation, 2003, 107(3): 363-369.
|
30 |
Figiel L, Kasprzak JD, Peruga J, et al. Heart-type fatty acid binding protein--a reliable marker of myocardial necrosis in a heterogeneous group of patients with acute coronary syndrome without persistent ST elevation[J]. Kardiol Pol, 2008, 66(3): 253-259.
|
31 |
Tanaka T, Sohmiya K, Kitaura Y, et al. Clinical evaluation of point-of-care-testing of heart-type fatty acid-binding protein (H-FABP) for the diagnosis of acute myocardial infarction[J]. J Immunoassay Immunochem, 2006, 27(3): 225-238.
|
32 |
Orak M, Ustundag M, Guloglu C, et al. The role of the heart-type fatty acid binding protein in the early diagnosis of acute coronary syndrome and its comparison with troponin i and creatine kinase-MB isoform[J]. Am J Emerg Med, 2010, 28(8): 891-896.
|
33 |
Morgenthaler NG, Struck J, Alonso C, et al. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin[J]. Clin Chem, 2006, 52(1): 112-119.
|
34 |
Khan SQ, Dhillon OS, O'Brien RJ, et al. C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study[J]. Circulation, 2007, 115(16): 2103-2110.
|
35 |
Reichlin T, Hochholzer W, Stelzig C, et al. Incremental value of copeptin for rapid rule out of acute myocardial infarction[J]. J Am Coll Cardiol, 2009, 54(1): 60-68.
|
36 |
Wang L, Xie L, Zhang Q, et al. Plasma nuclear and mitochondrial DNA levels in acute myocardial infarction patients[J]. Coron Artery Dis, 2015, 26(4): 296-300.
|
37 |
Wang R, Li N, Zhang Y, et al. Circulating microRNAs are promising novel biomarkers of acute myocardial infarction[J]. Intern Med, 2011, 50(17): 1789-1795.
|
38 |
De Rosa S, Fichtlscherer S, Lehmann R, et al. Transcoronary concentration gradients of circulating microRNAs[J]. Circulation, 2011, 124(18): 1936-1944.
|
39 |
Valadi H, Ekstrom K, Bossios A, et al. Exosome-mediated transfer of mrnas and microRNAs is a novel mechanism of genetic exchange between cells[J]. Nat Cell Biol, 2007, 9(6)654-659.
|
40 |
Ajit SK. Circulating microRNAs as biomarkers, therapeutic targets, and signaling molecules[J]. Sensors, 2012, 12(3)3359-3369.
|
41 |
Ji X, Takahashi R, Hiura Y, et al. Plasma mir-208 as a biomarker of myocardial injury[J]. Clin Chem, 2009, 55(11): 1944-1949.
|
42 |
Ai J, Zhang R, Li Y, et al. Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction[J]. Biochem Biophys Res Commun, 2010, 391(1): 73-77.
|
43 |
Wang GK, Zhu JQ, Zhang JT, et al. Circulating microrna: A novel potential biomarker for early diagnosis of acute myocardial infarction in humans[J]. Eur Heart J, 2010, 31(6): 659-666.
|
44 |
Cheng C, Wang Q, You W, et al. Mirnas as biomarkers of myocardial infarction: A meta-analysis[J]. PLoS One, 2014, 9(2): e88566.
|
45 |
Oerlemans MI, Mosterd A, Dekker MS, et al. Early assessment of acute coronary syndromes in the emergency department: The potential diagnostic value of circulating micrornas[J]. EMBO Mol Med, 2012, 4(11): 1176-1185.
|
46 |
Widera C, Gupta SK, Lorenzen JM, et al. Diagnostic and prognostic impact of six circulating micrornas in acute coronary syndrome[J]. J Mol Cell Cardiol, 2011, 51(5): 872-875.
|